Today, Fuse Vectors announces $5.2 million in pre-seed financing led by HCVC to revolutionize gene therapy development with its cell-free viral vector technology.

The optimized tyrosine-mutant AAV3 serotype vectors containing proapoptotic genes should prove useful for the potential gene therapy of human liver cancers.